The Novel BACE Inhibitor MK-8931 Dramatically Lowers CSF Aβ Peptides in Healthy Subjects: Results from a Rising Single Dose Study

被引：0

作者：

Forman, Mark

Tseng, Jack

Palcza, John

Leempoels, Jos ^{[1
]}

Ramael, Steven ^{[1
]}

Krishna, Gopal

Ma, Lei

Wagner, John

Troyer, Matthew

机构：

[1] SGS Life Sci Serv, Antwerp, Belgium

来源：

NEUROLOGY | 2012年 / 78卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

PL02004

引用

页数：3

共 33 条

[11] Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OSP-7238, a Novel Dipaptidyl Peptidase IV Inhibitor: Single Ascending Dose Study in Healthy Male Caucasian and Japanese Subjects
Woodruffe-Peacock, Charlotte
Brearley, Christopher
Brennan, Kieran
Lorch, Ulrike
[J]. DIABETES, 2009, 58 : A535 - A536
[12] Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects
Chow, Vincent
Oh, MyungShin
Gessner, Melissa A.
Fanjiang, Gary
[J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (02): : 246 - 255
[13] RESULTS FROM A RANDOMIZED, SINGLE-BLIND, SINGLE-DOSE, PARALLEL-GROUP STUDY IN HEALTHY SUBJECTS DEMONSTRATING PHARMACOKINETIC SIMILARITY BETWEEN ABP 710 AND INFLIXIMAB
Krishnan, E.
Chow, V.
Zhang, N.
Kaliyaperumal, A.
Kaur, P.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1181 - 1181
[14] ABBV-3373-A NOVEL IMMUNOLOGY ANTIBODY DRUG CONJUGATE: RESULTS FROM A FIRST-IN-HUMAN SINGLE ASCENDING DOSE STUDY IN HEALTHY SUBJECTS TO SUPPORT DOSE SELECTION FOR THE PROOF-OF-CONCEPT STUDY IN RHEUMATOID ARTHRITIS PATIENTS.
D'Cunha, R.
Kupper, H.
Arikan, D.
Zhao, W.
Ruzek, M.
Kang, B.
Doelger, E.
Carter, D.
Pang, Y.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S78 - S79
[15] Safety and pharmacokinetics of the nonnucleoside polymerase inhibitor, HCV-796: Results of a randomized, double-blind, placebo-controlled, ascending single-dose study in healthy subjects
Chandra, P.
Raible, D.
Moyer, L.
Harper, D.
Speth, J.
Villano, S.
Fruncillo, R.
[J]. JOURNAL OF HEPATOLOGY, 2006, 44 : S208 - S209
[16] CSL112, a Novel Formulation of Human Apolipoprotein A-I, Dramatically Increases Cholesterol Efflux Capacity in Healthy Subjects: A, Placebo-Controlled, Double-Blinded, Randomized Single Ascending Dose Study
Gille, Andreas
Easton, Rachael
Wright, Samuel
Shear, Charles
[J]. CIRCULATION, 2012, 126 (21)
[17] Safety, tolerability, pharmacokinetics, & pharmacodynamics of LC1 5-0444, a novel dipeptidyl peptidase IV inhibitor, in healthy male subjects: Single ascending dose and food effect study
Kim, Dong-Kyu
Lim, Kyoung Soo
Cho, Joo-Youn
Yu, Kyung-Sang
Shin, Sang-Goo
Kim, Sung-Ho
Kwon, O. Hwan
Lee, Sung-Hack
Lee, Jaeick
Kim, Jeong-Ae
Jang, In-Jin
Yim, Hyeon Joo
[J]. DIABETES, 2008, 57 : A588 - A588
[18] Safety, tolerability and pharmacokinetics of R1626, a novel nucleoside analog targeting hcv polymerase: Results from a phase I single dose escalation trial in healthy subjects.
Robson, R.
Berns, H.
Brand, M.
Feltner, S.
Hill, G.
Ipe, D.
Love, J.
Mannino, M.
O'Mara, E.
Tu, Y.
Washington, C.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S98 - S98
[19] TOLERABILITY, SAFETY, AND PHARMACOKINETICS OF THE NOVEL PDE INHIBITOR ZSP1601 IN HEALTHY SUBJECTS: A DOUBLE-BLIND, PLACEBO-CONTROLLED FIRST-IN-HUMAN SINGLE-DOSE, MULTIPLE-DOSE ESCALATION AND FOOD EFFECT STUDY
Li, Cuiyun
Zhang, Hong
Zhu, Xiaoxue
Wu, Min
Hu, Yue
Li, Xiaojiao
Li, Haijun
Chen, Xiaoxin
Peng, Yun
Ding, Hua Yan
Niu, Junqi
[J]. HEPATOLOGY, 2019, 70 : 1360A - 1361A
[20] A phase 1, open-Label, single ascending dose study in healthy subjects of the safety, tolerability and pharmacokinetics of ASLAN004, a novel IgG anti-IL-13 receptor alpha 1 Inhibitor
Lee, L.
Hajireen, H.
Ward, A.
Firth, C.
[J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (09) : B19 - B19

← 1 2 3 4 →